Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-HSCT for Thalassemia Major
NCT04009525Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jul 2019
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 4, open-label trial (3 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Overall Survival at 2 years and Thalassemia-free Survival at 2 years. Started Jul 2019; status: completed.
Beyond the preview
Go deeper on NCT04009525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04009525.